CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

J&J lines up $2.58B option to buy Sail, Flagship's in vivo CAR-T biotech

Positive
AI Analysis

Summary

Johnson & Johnson is paying $785 million upfront with a $2.58 billion option to acquire Sail Biomedicines, a Flagship Pioneering-backed in vivo CAR-T biotech company, expanding J&J's presence in the competitive cell therapy space.

Importance:7/10
Sentiment:
0.70
cell therapyCAR-Tin vivoM&Apartnership
Related Companies

Read the original article

Published by Endpoints News on July 30, 2026 4:32 AM

Read Original